Merck & Co. Joins Competitive BTK Research Space With $2.7bn ArQule Buy
Executive Summary
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.
You may also be interested in...
Loxo Lays Out Plans For BTK Inhibitor LOXO-305 In CLL
The company said investigators had been choosing the drug over Venclexta due to its less cumbersome administration, especially amid the COVID-19 pandemic.
LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.
Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First
As the first company with two approved chimeric antigen receptor T-cell therapies, Gilead’s Kite subsidiary has set a precedent by keeping the pricing the same as its first approved CAR-T, Yescarta.